tiprankstipranks
Tern PLC (GB:TERN)
LSE:TERN

Tern plc (TERN) AI Stock Analysis

18 Followers

Top Page

GB:TERN

Tern plc

(LSE:TERN)

Select Model
Select Model
Select Model
Underperform 40 (OpenAI - 5.2)
Rating:40Underperform
Price Target:
0.43 p
▼(-34.15% Downside)
Action:DowngradedDate:01/17/26
The score is primarily held down by poor financial performance (sharp revenue contraction, heavy losses, and negative operating/free cash flow). Technicals also point to a sustained downtrend with only tentative oversold stabilization signals. Valuation is difficult to support given negative earnings and no dividend yield data.
Positive Factors
Low Leverage
Tern's low debt-to-equity ratio indicates a conservative capital structure, providing financial stability and flexibility to navigate market fluctuations.
Negative Factors
Revenue Decline
A significant drop in revenue indicates challenges in business operations or market demand, which could hinder long-term growth and profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Tern's low debt-to-equity ratio indicates a conservative capital structure, providing financial stability and flexibility to navigate market fluctuations.
Read all positive factors

Tern plc (TERN) vs. iShares MSCI United Kingdom ETF (EWC)

Tern plc Business Overview & Revenue Model

Company Description
Tern plc (TERN) is a UK-based investment company that specializes in the technology sector, focusing on digital transformation and the Internet of Things (IoT). The company primarily invests in early-stage technology businesses that are developing...
How the Company Makes Money
Tern plc generates revenue primarily through capital appreciation from its investments in technology companies. The company's revenue model is centered on equity stakes in its portfolio firms, which may lead to significant returns when these compa...

Tern plc Financial Statement Overview

Summary
Financials are weak: steep revenue decline (-75.08%), very negative net margin (-216.76%), and negative EBIT/EBITDA margins. Cash flow is also pressured with negative operating and free cash flow and declining FCF growth (-25.81%). Low leverage (debt-to-equity 0.015) is a relative positive but does not offset losses and cash burn.
Income Statement
20
Very Negative
Balance Sheet
40
Negative
Cash Flow
30
Negative
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue29.40K17.40K199.23K-8.34M6.10M2.14M
Gross Profit29.40K17.40K199.23K66.01K63.78K151.16K
EBITDA-1.13M-1.18M-12.67M-10.25M0.000.00
Net Income-2.07M-3.77M-12.61M-10.45M4.58M803.89K
Balance Sheet
Total Assets10.94M11.31M13.15M25.18M32.76M24.30M
Cash, Cash Equivalents and Short-Term Investments74.00K382.21K297.56K931.76K1.96M2.13M
Total Debt170.00K161.11K418.20K0.000.000.00
Total Liabilities655.00K597.62K848.44K325.00K342.06K295.60K
Stockholders Equity10.29M10.71M12.30M24.85M32.42M24.00M
Cash Flow
Free Cash Flow-1.16M-1.57M-1.22M-2.20M-1.48M-1.19M
Operating Cash Flow-1.16M-1.57M-1.22M-2.20M-1.48M-1.19M
Investing Cash Flow-442.39K-406.39K151.92K-1.63M-2.50M-1.86M
Financing Cash Flow1.55M1.65M431.54K2.80M3.81M4.17M

Tern plc Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.65
Price Trends
50DMA
0.54
Positive
100DMA
0.53
Positive
200DMA
0.64
Positive
Market Momentum
MACD
0.07
Negative
RSI
52.95
Neutral
STOCH
48.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:TERN, the sentiment is Neutral. The current price of 0.65 is below the 20-day moving average (MA) of 0.66, above the 50-day MA of 0.54, and above the 200-day MA of 0.64, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 52.95 is Neutral, neither overbought nor oversold. The STOCH value of 48.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:TERN.

Tern plc Peers Comparison

Overall Rating
UnderperformOutperform
Sector (68)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
£178.27M37.635.22%0.80%22.80%-32.13%
68
Neutral
$18.00B11.429.92%3.81%9.73%1.22%
58
Neutral
£5.42M
51
Neutral
£4.43M-22.520.89%
46
Neutral
£36.75M-28.6149.22%1.73%-68.87%
41
Neutral
£1.55M-0.28-586.74%5.29%72.50%
40
Underperform
£5.07M-1.72-19.70%-77.04%86.67%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:TERN
Tern plc
0.68
-0.69
-50.37%
GB:TIDE
Crimson Tide
82.50
34.00
70.10%
GB:DSG
Dillistone
12.50
4.00
47.06%
GB:NET
Netcall
104.50
3.36
3.33%
GB:RDT
Rosslyn Data Technologies
1.90
-1.40
-42.42%
GB:GETB
GetBusy Plc
72.50
26.50
57.61%

Tern plc Corporate Events

Business Operations and StrategyLegal Proceedings
Tern plc Forfeits SVV2 Fund Interest and Faces Potential Default Costs
Negative
Jan 15, 2026
Tern plc has lost its entire limited partner interest in the Sure Valley Ventures Enterprise Capital Fund LP (SVV2) after being classified as a defaulting investor under the fund’s limited partnership agreement, following its request for rel...
Business Operations and Strategy
Tern Plc Publishes Investor Presentations from IoT Portfolio Companies
Positive
Jan 8, 2026
Tern Plc has announced that investor presentation materials from its recent online event featuring portfolio companies Device Authority and Talking Medicines are now available to view via published links, with a recording of the session to be host...
Business Operations and Strategy
Tern Plc Schedules Online Investor Presentation With Portfolio Companies
Positive
Dec 23, 2025
Tern Plc has scheduled an online investor presentation and QA session for 5.30 p.m. GMT on Wednesday 7 January 2026, to be led by members of its management team alongside executives from portfolio companies Device Authority and Talking Medicines. ...
Private Placements and Financing
Tern Plc Enhances Investment in Talking Medicines with New Convertible Loan Notes
Neutral
Dec 12, 2025
Tern Plc has been issued approximately £230,000 in new unsecured convertible loan notes by Talking Medicines Limited, in exchange for canceling existing short-term loans totaling about £180,000. This move increases Tern’s total con...
Business Operations and StrategyPrivate Placements and Financing
Tern Plc Faces Funding Challenges with SVV2 Commitment
Negative
Nov 28, 2025
Tern Plc has announced an update regarding its capital commitment to Sure Valley Ventures Enterprise Capital Fund LP (SVV2). The company has invested approximately £1.3 million into SVV2 but faces challenges in meeting further capital calls d...
Business Operations and StrategyPrivate Placements and Financing
Tern Plc Extends Convertible Loan Notes in Talking Medicines
Neutral
Nov 25, 2025
Tern Plc has announced the extension of the maturity dates for approximately £0.3 million of convertible loan notes in Talking Medicines Limited to 21 November 2029. This strategic move is expected to enhance Tern’s negotiating position...
Regulatory Filings and Compliance
Tern plc Announces Total Voting Rights Update
Neutral
Oct 31, 2025
Tern plc announced that its total issued ordinary share capital consists of 672,713,705 Ordinary Shares, each with one voting right, and none held in Treasury. This information is crucial for shareholders to determine their notification requiremen...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 17, 2026